Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash from Investing Activities for 13 consecutive years, with $27.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 157.52% to $27.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.3 million, a 111.78% increase, with the full-year FY2025 number at $32.3 million, up 111.78% from a year prior.
  • Cash from Investing Activities was $27.6 million for Q4 2025 at Madrigal Pharmaceuticals, up from -$207.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $163.9 million in Q1 2025 to a low of -$362.1 million in Q4 2023.
  • A 5-year average of -$27.1 million and a median of $17.4 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: soared 426.03% in 2021, then crashed 3171.65% in 2024.
  • Madrigal Pharmaceuticals' Cash from Investing Activities stood at $15.6 million in 2021, then skyrocketed by 324.39% to $66.4 million in 2022, then plummeted by 645.47% to -$362.1 million in 2023, then surged by 86.76% to -$47.9 million in 2024, then soared by 157.52% to $27.6 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Cash from Investing Activities are $27.6 million (Q4 2025), -$207.0 million (Q3 2025), and $47.9 million (Q2 2025).